Ipratropium bromide/salbutamol
The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide (an anticholinergic) and salbutamol sulfate (albuterol sulfate, a β2-adrenergic receptor agonist) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage). It is marketed by Boehringer Ingelheim as a metered dose inhaler (MDI) and nebuliser under the trade name Combivent. It is also marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva. The chemical is sold in India by Cipla as duolin.